ASX:ATXAmplia Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Amplia Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$0.08 0.00 (0.00 %) (As of 05/13/2020) Add Compare Share Today's RangeA$0.08Now: A$0.08▼A$0.0950-Day RangeA$0.08MA: A$0.08▼A$0.0852-Week RangeA$0.05Now: A$0.08▼A$0.34Volume77,249 shsAverage VolumeN/AMarket Capitalization$5.52 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlines Amplia Therapeutics Limited, a pharmaceutical company, focuses on advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its clinical development pipeline comprises two lead molecules, AMP945 and AMP886 that inhibits FAK. The company also manufactures and sells drugs. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in North Melbourne, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Amplia Therapeutics. Previous Next 3.8 Community Rank Outperform VotesAmplia Therapeutics has received 9 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAmplia Therapeutics has received 3 “underperform” votes. (Add your “underperform” vote.)Community SentimentAmplia Therapeutics has received 75.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Amplia Therapeutics and other stocks. Vote “Outperform” if you believe ATX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ATX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAmplia Therapeutics does not currently pay a dividend.Dividend GrowthAmplia Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amplia Therapeutics insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Amplia Therapeutics is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amplia Therapeutics is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmplia Therapeutics has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.89 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolASX:ATX Previous Symbol CUSIPN/A CIKN/A Webwww.ampliatx.com Phone61 2 8003 3650Debt Debt-to-Equity RatioN/A Current Ratio2.31 Quick Ratio2.24Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$34,227.00 Price / Sales161.17 Cash FlowA$0.02 per share Price / Cash Flow4.88 Book ValueA$0.13 per share Price / Book0.64Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares66,463,200Market Cap$5.52 million Next Earnings DateN/A OptionableNot Optionable Receive ATX News and Ratings via Email Sign-up to receive the latest news and ratings for ATX and its competitors with MarketBeat's FREE daily newsletter. Amplia Therapeutics (ASX:ATX) Frequently Asked Questions How has Amplia Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Amplia Therapeutics' stock was trading at A$0.08 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ATX shares have increased by 10.7% and is now trading at A$0.08. View which stocks have been most impacted by Coronavirus. Has Amplia Therapeutics been receiving favorable news coverage? News coverage about ATX stock has trended negative on Sunday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Amplia Therapeutics earned a daily sentiment score of -2.4 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Amplia Therapeutics. Who are some of Amplia Therapeutics' key competitors? Some companies that are related to Amplia Therapeutics include Prescient Therapeutics (PTX), Nuformix (NFX), Inhibitor Therapeutics (INTI), Destiny Pharma (DEST), Agronomics (ANIC), Biocardia (BCDA), CAN-FITE BIOPHA/S (CANF), Can-Fite Biopharma (CANF), Crescita Therapeutics (CTX), Immuron (IMC), Kane Biotech (KNE), Collagen Solutions (COS), Devonian Health Group (GSD), Hvivo (HVO) and Realm Therapeutics (RLM). View all competitors. Who are Amplia Therapeutics' key executives? Amplia Therapeutics' management team includes the following people: Dr. John Lambert, Chief Exec. OfficerMr. Jeff Carter MAppFin, BFinAdmin, Chief Financial Officer (Age 61)Mr. Andrew J. Cooke L.L.B., LLB, FAICS, MAICD, FGIA, FCIS, Company Sec. & Independent Non-Exec. Director (Age 59)Mark Devlin, Chief Scientific AdvisorDr. Frank Gelder, Founding Scientist What is Amplia Therapeutics' stock symbol? Amplia Therapeutics trades on the ASX under the ticker symbol "ATX." What is Amplia Therapeutics' stock price today? One share of ATX stock can currently be purchased for approximately A$0.08. How big of a company is Amplia Therapeutics? Amplia Therapeutics has a market capitalization of $5.52 million and generates $34,227.00 in revenue each year. What is Amplia Therapeutics' official website? The official website for Amplia Therapeutics is www.ampliatx.com. How can I contact Amplia Therapeutics? The company can be reached via phone at 61 2 8003 3650. This page was last updated on 7/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
